Le Lézard
Classified in: Business
Subject: STR

Canadian Investment Regulatory Organization Trade Resumption - BABY


TORONTO, Nov. 13, 2023 /CNW/ - Trading resumes in:

Company: Else Nutrition Holdings Inc.

TSX Symbol: BABY 

All Issues: Yes

Resumption (ET): 9:00 AM

CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Canadian Investment Regulatory Organization (CIRO) ? Halts/Resumptions


These press releases may also interest you

at 20:25
Aura Minerals Inc. ("Aura" or the "Company") announces that it has filed its unaudited consolidated financial statements and management discussion and analysis (together, "Financial and Operational Results") for the period ended March 31, 2024...

at 20:20
Planned Parenthood of Metropolitan Washington, DC (PPMW) recently received an Underserved Communities Projects grant from Montgomery County, Maryland, to grow the PPMW Promotoras de Salud community health outreach program. The Promotoras de Salud...

at 20:10
WHY: Rosen Law Firm, a global investor rights law firm, reminds those who held the common stock of Northern Genesis Acquisition Corp. n/k/a The Lion Electric Company as of the record date of March 18, 2021 for the merger with the then-private The...

at 20:06
LEEF Brands, Inc. ("LEEF" or the "Company") , a premier vertical cannabis operator, today announces an update regarding the Company's convertible debentures, further to its press release dated April 18, 2024. In a strategic financial restructuring,...

at 20:00
Pomerantz LLP is investigating claims on behalf of investors of  CVS Health Corporation ("CVS" or the "Company") .  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980....

at 20:00
Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980....



News published on and distributed by: